Postmortem genetic testing of the ryanodine receptor 2 (RYR2) gene in a cohort of sudden unexplained death cases

2012 ◽  
Vol 127 (1) ◽  
pp. 139-144 ◽  
Author(s):  
M. K. Larsen ◽  
K. E. Berge ◽  
T. P. Leren ◽  
P. H. Nissen ◽  
J. Hansen ◽  
...  
ESC CardioMed ◽  
2018 ◽  
pp. 685-688
Author(s):  
Najim Lahrouchi ◽  
Elijah R. Behr ◽  
Connie R. Bezzina

Postmortem analysis of young sudden cardiac death patients leads to a diagnosis of structural cardiac disease in the majority of cases. However, despite thorough autopsy, including toxicological and histological analysis, in one-third of patients no cause of death is identified and these patients are classified as sudden unexplained death or sudden arrhythmic death syndrome. Postmortem genetic testing in these patients can establish a genetic aetiology of sudden cardiac death, which allows for appropriate screening and management of family members at risk of sudden cardiac death.


2008 ◽  
Vol 129 (3) ◽  
pp. 391-397 ◽  
Author(s):  
Elisa Carturan ◽  
David J. Tester ◽  
Brian C. Brost ◽  
Cristina Basso ◽  
Gaetano Thiene ◽  
...  

2012 ◽  
Vol 87 (6) ◽  
pp. 524-539 ◽  
Author(s):  
David J. Tester ◽  
Argelia Medeiros-Domingo ◽  
Melissa L. Will ◽  
Carla M. Haglund ◽  
Michael J. Ackerman

Author(s):  
Jacqueline Neubauer ◽  
Shouyu Wang ◽  
Giancarlo Russo ◽  
Cordula Haas

AbstractSudden unexplained death (SUD) takes up a considerable part in overall sudden death cases, especially in adolescents and young adults. During the past decade, many channelopathy- and cardiomyopathy-associated single nucleotide variants (SNVs) have been identified in SUD studies by means of postmortem molecular autopsy, yet the number of cases that remain inconclusive is still high. Recent studies had suggested that structural variants (SVs) might play an important role in SUD, but there is no consensus on the impact of SVs on inherited cardiac diseases. In this study, we searched for potentially pathogenic SVs in 244 genes associated with cardiac diseases. Whole-exome sequencing and appropriate data analysis were performed in 45 SUD cases. Re-analysis of the exome data according to the current ACMG guidelines identified 14 pathogenic or likely pathogenic variants in 10 (22.2%) out of the 45 SUD cases, whereof 2 (4.4%) individuals had variants with likely functional effects in the channelopathy-associated genes SCN5A and TRDN and 1 (2.2%) individual in the cardiomyopathy-associated gene DTNA. In addition, 18 structural variants (SVs) were identified in 15 out of the 45 individuals. Two SVs with likely functional impairment were found in the coding regions of PDSS2 and TRPM4 in 2 SUD cases (4.4%). Both were identified as heterozygous deletions, which were confirmed by multiplex ligation-dependent probe amplification. In conclusion, our findings support that SVs could contribute to the pathology of the sudden death event in some of the cases and therefore should be investigated on a routine basis in suspected SUD cases.


2018 ◽  
Vol 8 (3) ◽  
pp. 738-751 ◽  
Author(s):  
Gina Liu ◽  
Heather MacLeod ◽  
Gregory Webster ◽  
Elizabeth M. McNally ◽  
Suzanne M. O’Neill ◽  
...  

A significant portion of sudden death cases result from an underlying genetic etiology, which may be determined through postmortem genetic testing. The National Association of Medical Examiners (NAME) recommends that an appropriate postmortem sample is saved on all sudden death cases under the age of 40. Genetic counselors (GCs) play an important role in this process by working with medical examiners and coroners (ME/Cs) to recommend and interpret specific testing and to guide family members. A survey sent to the National Society of Genetic Counselors was designed and implemented to learn more about the experiences of genetic counselors who had considered or ordered postmortem genetic testing. Results showed that cardiovascular GCs were significantly more willing to recommend genetic testing in younger age decedents (ages 10, 18, 30, 40, and 50) compared to other specialty GCs ( p<0.05, Chi-square). Thirty-seven percent (7 of 19) of GCs reported insurance covering some portion of genetic testing. Participants also reported highest success for DNA extractions with fresh and frozen blood, reinforcing NAME recommendations for appropriate sample collection for postmortem genetic testing. Overall, participating GCs demonstrated a very good understanding for the appropriate use of postmortem genetic testing and did identify suspected barriers of cost and lack of insurance coverage as deterrents. With the rapid decrease in costs for diagnostic genetic testing, ME/C awareness of NAME recommendations for sample collection and storage remain important to facilitate postmortem genetic testing.


2017 ◽  
Vol 131 (5) ◽  
pp. 1211-1219 ◽  
Author(s):  
Marina Gago-Díaz ◽  
Eva Ramos-Luis ◽  
Silvia Zoppis ◽  
Esther Zorio ◽  
Pilar Molina ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document